Market Research Logo

Global Market for Cell Therapy & Tissue Engineering 2019

Global Market for Cell Therapy & Tissue Engineering 2019

EXECUTIVE SUMMARY – Market for Cell Therapy and Tissue Engineering


This report contains analysis of developments across the rapidly evolving fields of cell therapy (CT) and tissue engineering (TE), with a focus on competitive dynamics and commercial successes and failures. Cell therapy is the utilization of living cells for the treatment or potential cure of human disease or injury. Tissue engineering (TE) is a field of medicine that is focused on restoring, maintaining, improving, or replacing damaged tissues and organs through the combination of scaffolds, cells, and biologically active molecules. This report highlights important issues across these interrelated fields, including market challenges, economic evaluation, policy improvements, pricing and reimbursement, and rates of global adoption. Because several of the developments in cell therapy and regenerative medicine (RM) are closely related, the report also gives an overview of the regenerative medicine industry.

One of the earliest examples of cell therapy was the transplantation of hematopoietic stem cells (HSCs) in the 1950s from a donor to a recipient to create a bone marrow transplant, which today represents a well-established type of cell therapy practiced worldwide. Newer forms of cell therapy involve the delivery of other cell types to a patients, including CAR-T and CAR-NK cells, mesenchymal stem cells (MSCs), neural stem cells (NSCs), and to a lesser degree, induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), directly reprogrammed cells, and other pluripotent and differentiated cell types.

Because tissue engineering (TE) integrates cellular products with scaffolds, it is integral to the field of cell therapy. These scaffolds are often made using naturally occurring proteins or biocompatible synthetic polymers. Some TE products are made using a protein-based extracellular matrix (ECM) obtained from a donor. The ECM is prepared by removing the cells by a process called decellularization. Cells and growth factors are seeded on to the ECM to develop a tissue or organ.

Cell therapy, gene-modified cell therapy, gene therapy and tissue engineering are the four pillars of regenerative medicine (RM). These therapies have the potential to favorably change the quality of life and improve the health status of patients suffering from cellular defects, genetic diseases, neurodegenerative diseases, tissue malignancies, and other medical conditions. The combined efforts of research and clinical scientists in academic, translational and industry settings have led us to the development of several approved commercial firsts, such as Glybera, Kymriah, Yescarta, Holoclar, and Luxturna.

Today, the healthcare environment is under great pressure to develop therapies capable of reversing or significantly impacting the progression of serious illnesses. The arrival of regenerative medicine (RM) has been propelled by advances across the cell therapy (CT) and tissue (TE) engineering industries. Regenerative medicines have the potential to transform the healthcare landscape by providing transformative, durable and potentially curative outcomes to human injuries, diseases, and genetic disorders.

With the number of regenerative medicine firms expanding exponentially, over a thousand clinical trials ongoing worldwide (>50% in oncology), and key strategic alliances underway among industry and academic partners, the success of regenerative medicine therapies seems to be a certainty. This report reports the market for regenerative medicine (RM) products approved worldwide, including 44 approvals across the U.S., Europe, South Korea, India, China, Japan, Australia and New Zealand. Additionally, the RM sector saw venture capital investment grow from a mere $200 million in 2010 to a massive $14.6 billion in 2018. This massive investment and market growth in the RM space indicates a future with heavy competition.

Thus, the main objectives of this cell therapy (CT) and tissue engineering (TE) report are to provide the reader with the following details:

  • Total global financings in cell therapy and gene-modified cell therapy space.
  • Corporate partnerships in cell therapy and gene-modified cell therapy space.
  • Private placements and venture financings in cell therapy and gene-modified cell therapy space.
  • The history of cell therapy from 1944 to present.
  • Potential applications of cell therapy.
  • FDA-approved cell therapy products made from human HSCs.
  • Leading induced pluripotent stem cell (iPSC) companies.
  • Potential applications of iPSCs.
  • Various sources of mesenchymal stem cells (MSCs).
  • Various clinical applications of mesenchymal stem cells (MSCs).
  • Various biologically-active substances secreted by mesenchymal stem cells (MSCs).
  • The estimated consumption of MSCs in the cell therapy industry (future projections).
  • Other cell types with the potential to disrupt MSC’s demand.
  • Approved MSC-based cell therapy products in the global market.
  • Diseases addressed by neural stem cells in clinical trials.
  • Leading companies in neural stem cells space.
  • Indications addressed by human embryonic stem cells (hESCs) in clinical trials.
  • Leading cell therapy startups.
  • Cell therapies with RMAT designation.
  • Number of gene-modified cell therapy companies.
  • Number of CAR-T cell therapy companies.
  • Number of NK cell therapy companies in the world.
  • Approved TE products in the global market.
  • Number of cell therapy clinical trials.
  • Diseases addressed by MSCs in clinical trials.
  • Number of clinical trials using MSCs.
  • Anticipated clinical events in cell therapy space.
  • Number of clinical trials in gene-modified cell therapy space.
  • Anticipated developments in cell therapy space in 2019.
  • Number of clinical trials in Tissue Engineering (TE) space.
  • Approved cell therapy products by geography.
  • Approved tissue engineering (TE) products by geography.
  • Cell and gene therapy manufacturing capacities in the U.S. and Europe.
  • Select CMOs/CDMOs in cell and gene therapy space.
  • Projected outsourcing market for the manufacture of cell and gene therapy products.
  • Projected growth of cell manufacturing capacity.
  • Global market for cell therapy products by geography.
  • Global market for tissue-engineered products by geography.
  • Profiles of companies that are developing products in cell therapy and tissue engineering spaces.
For companies involved with the commercialization of cell therapy (CT) and tissue engineering (TE) products, this report provides market size determinations, coupled with five-year forecasts and trends. It analyzes emerging market forces, highlights industry partnerships and deal-making, and captures the progression of cell therapy and tissue engineering products across various states of development. With the rapid evolution of this market sector, this global strategic report is your guide to research advances, clinical breakthroughs, and commercialized successes.


  • REPORT OVERVIEW
    • Statement of the Report
    • Executive Summary
      • Cell Therapy Industry
      • Tissue Engineering Industry
  • BRIEF OVERVIEW OF REGENERATIVE MEDICINE (RM) INDUSTRY
    • Number of RM Companies
      • Table Number of RM Companies by Geography, 2018
    • RM Product Approvals in 2017/2018
      • Table RM Product Approvals in 2017/2018
      • RM Products Approved Worldwide
        • Table RM Products with Marketing Approval by Geography/Country
        • Table Approved RM Products by Therapy Type
        • Table Approved RM Products by Indication
      • Approved RM Products in Australia
        • Table The Lone Cell Therapy Product Approved in Australia
      • The Two RM Products Approved in Canada
        • Table The Two RM Products Approved in Canada
      • RM Product Approved in China
        • Table RM Product Approved in China
      • Approved RM Products in Europe
        • Table Approved RM Products in Europe
        • Table RM Products with Withrawn Approvals in Europe
      • Approved RM Products in India
        • Table Approved RM Products in India
      • RM Products Approved in Japan
        • Table RM Products Approved in Japan
      • RM Products Approved in New Zealand
        • Table RM Products Approved in New Zealand
      • RM Products Approved in South Korea
        • Table RM Products Approved in South Korea
      • Approved RM Products in the U.S.
        • Table Approved RM Products in the U.S.
    • RM Products with RMAT Designation
      • Table RM Products with RMAT Designation
    • Total RM Clinical Trials
      • Table Total RM Clinical Trials by Phase, 2017/2018
      • Total RM Clinical Trials by Technology Type
        • Table Total RM Clinical Trials by Technology Type
        • Table Select Anticipated RM Industry Clinical Trial Data Readouts: 2019
    • RM Industry: Total Global Financings, 2018
      • Table RM Industry: Total Global Financings, 2018
      • Total Financings to RM Industry by Type and Year, 2016-2018
        • Table Total Financings to RM Industry by Type and Year, 2016-2018
      • Corporate Partnerships (Upront Payments) in RM Industry, 2018
        • Table Corporate Partnerships (Upront Payments) in RM Industry, 2018
      • Private Placements and Venture Fianancings in RM Industry, 2018
        • Table Private Placements and Venture Fianancings in RM Industry, 2018
      • Public Offerings (IPOs & Follow-Ons) in RM Industry, 2018
        • Table Public Offerings (IPOs & Follow-Ons) in RM Industry, 2018
      • Total Merger & Acquisition within RM Industry by Year, 2016-2018
        • Table Total Merger & Acquisition within RM Industry by Year, 2016-2018
    • Anticipated RM Product Launches
      • Estimated RM Treated Patients, 2018-2030
    • Top 20 RM Companies by Pipeline Size
      • Table Top 20 RM Companies by Pipeline Size, 2018
  • CELL THERAPY (CT): AN OVERVIEW
    • Cell Therapy Timeline
      • Table Timeline of Notable Events in Cell Therapy Sector
      • Potential Applications of Stem Cells in Personalized Medicine
      • Types of Stem Cells Used in Cell Therapy
    • Hematopoietic Stem Cells (HSCs)
      • Table Common Indications for HSCTs
      • FDA-Approved Cell Therapies Made from Hematopoietic Stem Cells
        • Table FDA-Approved Allogeneic HSCs
    • Induced Pluripotent Stem Cells
      • Table Leading iPSC Therapy Companies
      • Potential Applications of iPSCs
    • Mesenchymal Stem Cells (MSCs)
      • Clinical Applications of MSCs
      • Biologically Active Substances Secreted by MSCs
        • Table Groth Factors Secreted by MSCs
        • Table Cytokines Secreted by MSCs
        • Table Chemokines Secreted by MSCs
        • Table Forecasted Approved MSC-Based Product Types, 2020-2060
        • Table Estimated MSC Consumption in 2040
      • Approved MSC-Based Products
        • Table MSC-Based Approved Products
    • Neural Stem Cells (NSCs)
      • Diseases Addressed by Neural Stem Cells in Clinical Trials
        • Table Diseases Addressed by Neural Stem Cells in Clinical Trials
      • Leading Players in NSC Clinical Trials
        • Table Select List of Companies Active in Clinical Trials using NSCs
      • Indications Addressed by NSCs in Clinical Trials
    • Embryonic Stem Cells (ESCs)
      • Indications Addressed by ESCs
        • Table Companies involved in hESCs Projects and the Diseases Addressed
    • Notable Events in Cell Therapy Space, 2018
      • Table Notable Events in Cell Therapy Space, 2018
      • Orphan Drug Designation for Pluristem's PLX-R18
      • Positive Data from Biocardia's CardiAMP
      • Survival Outcome Announced by Mesoblast for its Phase III Remestemcel-L
      • Topline Results for NeoCart Announced by Histogenics
      • Fast Track Designation for Nohla's Dilanubicel (NLA101)
      • RMAT Designation for Cellerant's Romyelocel-L
    • Top 16 Stem Cell Therapy Startups
      • Table Top 16 Stem Cell Therapy Start Ups
    • Cell Therapies with RMAT Designation
      • Table Cell Therapy Product Candidates with RMAT Designation
      • RMAT Designation for Romyelocel-L
      • RMAT Designation for CLBS14-RfA
      • RMAT Designation for CAP-1002
      • RMAT Designation for MPC Therapy
      • RMAT Designation for CEVA101
      • RMAT Designation for Multistem
      • RMAT Designation for AST-OPC1
      • RMAT Designation for ATIR101
      • RMAT Designation for Ixmyelocel-T
      • RMAT Designation for jCell
      • RMAT Designation for RVT-802
  • GENE-MODIFIED CELL THERAPY
    • Number of Gene-Modified Cell Therapy Companies
      • Table Number of Gene-Modified Cell Therapy Companies
    • CAR-T Cell Therapy
      • Global Distribution of CAR-T Cell Therapy Companies
        • Table Geographical Distribution of CAR-T Cell Therapy Companies
    • Select Events in Cell-Based Immuno-Oncology Space, 2018
      • Table Select Events in Cell-Based Immuno-Oncology Space, 2018
      • Leading Cancer Immunotherapy Companies
        • Table Top Ten Cancer Immunotherapy Companies
      • Major Immunotherapy Startups
        • Table Major Immunotherapy Startups
    • T-Cell Receptor Therapy (TCR Therapy)
      • Process of TCR-Engineered T Cells Therapy
      • Promise of TCR Therapy in Solid Tumors
      • Clinical Progress of TCRs
        • Table Select Ongoing Clinical Trials Involving TCRs
      • Venture Activity and Deal Flow for the Development of TCR Therapies
        • Table Venture Activity and Deal Flow for the Development of TCR Therapies, 2018
    • Natural Killer (NK) Cell Therapies
      • CAR-Expressing NK Cells
        • Table CAR-NK Cells in Clinical Trials
        • Table Select NK Cell Therapies in Clinical and Preclinical Development
    • Tumor Infiltrating Lymphocytes (TILs) Therapy
      • Table Examples of Clinical Trials using TILs
    • Marrow-Infiltrating Lymphocytes (MILs)
    • Gamma-Delta T-Cells Therapy
      • Big Biopharma's Interest in Gamma-Delta T-Cells Therapy
        • Table The Two Gamma-Delta T-cell Therapy Companies
    • Dendritic Cell (DC) Therapy
      • Cancer Types Targeted by DC Therapy Studies
      • Ongoing Clinical Trials Testing DC Vaccines
        • Table Select Ongoing Clinical Trials Testing DC Vaccines
  • TISSUE ENGINEERING
    • Smart Biomaterials in Tissue Engineering
      • Biosynthetic Materials
      • 3D Printable Inks
    • Synthetic and Naturally-Derived Scaffolds
    • Tissue Substitutes
      • Cell-Based Tissues
      • Collagen
        • Table Approved TE Products
    • TWO Key Developments in Tissue Engineering Space in 2018
      • Table Select Events in Tissue Engineering Space, 2018
      • FDA Approval for RECELL
  • CLINICAL TRIAL LANDSCAPE: REGENERATIVE MEDICINE
    • Table Number of Clinical Trials in RM Sector, 2017-2018
    • Number of Patient Participation in RM Clinical Trials, 2018
      • Table Number of Patient Participation in RM Clinical Trials, 2018
    • Number of Clinical Trials by Indications in the RM Sector, 2018
      • Table Number of Clinical Trials by Indications in the RM Sector, 2018
  • CELL THERAPY CLINICAL TRIALS
    • Table Number of Cell Therapy Clinical Trials, 2018
    • Cell Therapy Clinical Trials by Indication, 2018
    • Mesenchymal Stem Cells (MSCs) in Clinical Trials
      • Table Number of Clinical Trials using MSCs
      • Number of Clinical Trials and Number of Patients Treated using MSCs
        • Table Number of Clinical Trials and Number of Patients Treated using MSCs
      • MSC Target Indication, Total Trials and Cells used per Patient
        • Table MSC Target Indication, Total Trials and Cells used per Patient
      • Number of Clinical Trials using MSCs
      • Indications for Which MSCs are Tested in Clinical Trials
      • Clinical Trials using MSCs by Geography/Country
    • Clinical Trials using hESCs
      • Table The 29 Clinical Trials using hESCs
    • Anticipated Clinical Events in Cell Therapy Space
      • BLA Filing for Remestemcel-L
      • Conditional MA Application for Tab-Cel
      • MultiStem being Developed for Multiple Diseases
        • Table Select Anticipated Clinical Data and Events in Cell Therapy Space
  • CLINICAL TRIALS IN GENE-MODIFIED CELL THERAPIES
    • Table Numbert of Gene Modified Cell Therapy Clinical Trials, 2017-2018
    • The Most Common Target Antigens for CAR-T Cell Therapies
    • Antigens other than CD19 in Clinical Trials Targeted by CAR-T
      • Table Antigens other than CD19 in Clinical Trials Targeted by CAR-T
    • Antigens Targeted by CAR-T in Solid Cancers in Clinical Trials
    • Anticipated Developments in CAR-T Space
      • Table Anticipated Developments in CAR-T Space
  • CLINICAL TRIALS IN TISSUE ENGINEERING SPACE
    • Table Number of Clinical Trials in TE Space, 2017-2018
    • Anticipated Clinical Events in Tissue Engineering Space, 2019/2020
      • Table Anticipated Clinical Events in Tissue Engineering Space, 2019/2020
  • APPROVED CELL THERAPY PRODUCTS WORLDWIDE
    • Number of Cell Therapies Approved by Geography
      • Table No. of Approved Cell Therapy & Gene-Modified Cell Products by Region/Country
    • Cell Therapy Products by Therapy Type
      • Table Cell Therapy Products by Therapy Type
    • Indications Addressed by the Approved Cell Therapy Products
      • Table Indications Addressed by the Approved Cell Therapy Products
    • Approved Cell Therapy Product in Australia
      • Table Approved Cell Therapy Product in Australia
      • Ortho-ACI
    • Cell Therapy Products Approved in Canada
      • Table Cell Therapy Products Approved in Canada
    • Approved Cell Therapies in Europe
      • Table Approved Cell Therapy and Gene-Modified Cell Therapies in Europe
      • Yescarta (Axicabtagene Ciloleucel)
      • Kymriah (Tisagenlecleucel)
      • Alofisel
      • Holoclar
    • Approved Cell Therapy Products in India
      • Table Approved Cell Therapy Products in India
      • Cartigrow
      • Ossgrow
      • Apceden
      • Stempeucel
    • Approved Cell Therapy Product in Japan
      • TEMCELL HS
        • Table Approved Cell Therapy Product in Japan
    • Approved Cell Therapy Product in New Zealand
      • Table Approved Cell Therapy Product in New Zealand
      • Prochymal
    • Approved Cell Therapy Products in South Korea
      • KeraHeal-Allo
      • Neuronata-R
      • Cupistem
        • Table Approved Cell Therapy Products in South Korea
      • Cartistem
      • Cellgram-AMI
      • CureSkin Inj.
      • Queencell
      • RMS Ossron
      • Immuncell LC
      • CreaVax-RCC
      • KeraHeal
      • Chondron
    • Approved Cell Therapy Products in the U.S.
      • Table Approved Cell Therapy Products in the U.S.
      • HPC, Cord Blood
      • Clevecord
      • HPC, Cord Blood (Bloodworks)
      • HPC, Cord Blood (LifeSouth Copmmunity Blood Center)
      • Allocord
      • Ducord
      • HPC, Cord Blood (Clinimmune Labs)
      • Hemacord
      • Laviv (Azficel-T)
      • Provenge (Sipuleucel-T)
  • APPROVED TISSUE ENGINEERED (TE) PRODUCTS
    • Table Approved TE Products in Europe
    • Spherox
      • Table Approved TE Products in Japan
    • HeartSheet
    • JACC
    • JACE
      • Table Approved TE Products in South Korea
    • Kaloderm
    • Holoderm
      • Table Approved TE Products in the U.S.
    • MACI
      • Table Addressable Cartilage Repair Patient Population in the U.S.
    • GINTUIT
  • MANUFACTURING OF CELLS FOR CELL THERAPIES
    • Table Expenditure Categories in Cell Manufacturing
    • Cost of Cell Manufacture
      • Table The Impact of Head Count on Labor Cost
      • Cost of Cell Manufacture in a Partially-Automated Facility
        • Table Cost of Manufacture in a Partially-Automated Facility
      • Cost of Manufacture in a Fully-Automated Facility
        • Table Cost of Manufacture in a Fully-Automated Facility
      • Net Present Cost (NPC) of the Three Methods
    • In-House Gene Therapy Manufacturing Capabilities of Select Big and Mid Pharma
      • Table In-House Gene Therapy Manufacturing Capabilities of Select Big and Mid Pharma
    • External Gene Therapy Manufacturing by Big and Mid Pharma
      • Table External Gene Therapy Manufacturing by Big and Mid Pharma
    • Cell Manufacturing Capacities in North America
      • Table Cell and Gene Therapy Manufacturing Capacities in North America
    • Cell Manufacturing Capacities in Europe
      • Table Cell and Gene Therapy Manufacturing Capacities in Europe
  • CMOs & CDMOs
    • Table Select CDMOs in Cell and Gene Therapy Space
    • Appropriate Phase for Outsourcing
      • Table The Appropriate Phase for Outsourcing a Cell or Gene Therapy Project
    • Important Points Condirered while Fixing a CMO/CDMO
      • Table Important Points Considered While Fixing a CDMO
    • In-House vs. Outsourcing
      • Table Share of In-House and CDMO Manufacture of Cell and Gene Therapies
    • Number of Cell Gene Therapy CMOs/CDMOs in Europe
    • Projected Growth of CMOs and CDMOs
    • Projected Growth of Cell Manufacturing Capacity
  • MARKET ANALYSIS
    • Global Market for RM Products
      • Table Global Market for RM Products by Therapy Type, 2018-2025
      • Global RM Products Market by Geography
        • Table Global Market for RM Products by Geography, 2018-2025
    • Global Market for Cell Therapy Products
      • Table Global Market for Approved Cell Therapy Products, 2018-2025
    • Global Market for Gene-Modified Cell Therapy Products
      • Table Global Market for CAR-T Cell Therapy Products, 2018-2025
      • Global Market for CAR-T Therapy by Geography
      • Global Market for CAR-T Therapy by Country
      • Global Market for CAR-T Cell Therapy by Targeted Antigens
      • Competitive Landscape
        • Table CAR-T Cell Therapy – Competitive Landscape
    • Global Market for Tissue-Engineered Products
      • Table Global Market for Tissue-Engineered Products, 2018-2025
  • COMPANY PROFILES
    • Adaptimmune Therapeutics plc
      • Table Adaptimmune's Pipeline Programs
    • Admedus Ltd.
      • CardioCel
      • CardioCel 3D
      • VascuCel
    • Advanced Bioscience Laboratories, Inc.
      • Biomanufacturing Services
    • Allogene Therapeutics, Inc.
      • Table Allogene Therapeutics' Pipeline of Allogeneic T-Cell Product Candidates
    • AlloSource, Inc.
    • Ambys Medicines, Inc.
    • Anterogen Co., Ltd.
      • Cupistem Injection
      • Queencell
    • APAC Biotech Pvt., Ltd.
      • APCEDEN
    • apceth Biopharma GmbH
      • Table apceth's Pipeline Overview
    • Asterias Biotherapeutics, Inc.
      • Table Asterias' Pipeline Programs
    • Atara Biotherapeutics, Inc.
      • Table Atara's Pipeline of T-Cell Immunotherapy and CAR-T Product Candidates
    • Athersys, Inc.
      • MultiStem
        • Table Athersys' Clinical Programs using MultiStem
    • ATVIO Biotech Ltd.
      • AT132 for X-Linked Myotubular Myopathy
      • AT342 for Crigler-Najjar Syndrome
      • AT982 for Pompe Disease
      • AT307 for CASQ2-CPVT
        • Table Audentes' Product Candidates
    • AveXis, Inc.
      • AVXS-101
    • Avita Medical Ltd.
      • RECELL System
      • ReGenerCell
      • ReNovaCell
    • Batavia Bioscience B.V.
      • Research Services
      • Development Services
      • Characterization Services
      • Manufacturing Services
      • Consultancy Services
    • Bellicum Pharmaceuticals, Inc.
      • Table Bellicum Pharmaceuticals' Product Candidates
    • Betalin Therapeutics
      • Engineered Micro-Pancreas (EMP)
    • BioCardia, Inc.
      • Table BioCardia's Advanced Pipeline
    • BioReliance Corporation
    • Biosolution Co., Ltd.
      • Table Biosolution's Products and Product Candidates
    • Biostage, Inc.
      • Cellspan Esophageal Implants
      • Cellspan Bronchial Implants
      • Cellspan Tracheal Implants
    • Biovian Oy
    • BlueRock Therapeutics
      • BlueRock's Pipeline
    • Bone Therapeutics SA
      • ALLOB
      • JTA-004
    • Brainstorm Cell Therapeutics, Inc.
      • NurOwn
        • Table Brainstorm's Clinical Programs
    • Brammer Bio, LLC
      • Services
      • Process Development
      • Gene Therapy Manufacturing
      • Viral Vectors
    • Caladrius Biosciences, Inc.
      • Table Caladrius' Proprietary Technology Platforms and Pipeline Programs
    • Carina Biotech
      • CNA1003
    • CARsgen Therapeutics, Ltd.
      • Table CARsgen Therapeutics' Product Candidates
    • Cell Cure Neurociences Ltd.
      • OpRegen
    • Cellerant Therapeutics, Inc.
      • Table Cellerant's Program Pipeline for Blood Disorders
    • Cell Medica Limited
      • Table Cell Medica's Product Pipeline
    • Cell Therapy Catapult, Ltd.
      • Capabilities
    • Cellular Biomedicine Group, Inc.
      • Table CBG's Immuno-Oncology Stem Cell Therapy Pipeline
    • Cellular Dynamics International, Inc.
    • Celonic AG
    • Celyad SA
      • Table Celyad's Programs' Status at a Glance
    • Farmaceutici S.p.A.
      • Holoclar
    • Cobra Biologics Ltd.
      • DNA Platform Process, Development and Scale Up
      • Viral Vector Platform Process
    • co-don AG
      • ACT3D
    • Corestem, Inc.
      • NEURONATA-R inj.
        • Table Corestem's Key Clinical Pharmaceutical Development
    • Cynata Therapeutics, Ltd.
    • Cytori Therapeutics, Inc.
      • Table Cytori's Cell Therapy Development Pipeline
    • Dendreon Pharmaceuticals, Inc.
      • PROVENGE
    • Enzyvant, Inc.
      • RVT-802
    • Eureka Therapeutics, Inc.
      • ARTEMIS
      • E-ALPHA
        • Table Eureka's Development Pipeline
    • Fate Therapeautics, Inc.
      • Table Fate Therapeutics' Cell Therapy Product Candidates Pipeline
    • Fibrocell Technologies, Inc.
      • Fibrocell's Pipeline
        • Table Fibrocell's Personalized Biologics Pipeline
    • FUJIFILM Diosynth Biotechnologies, Inc.
      • Services
    • Gamida Cell Ltd.
      • Table Gamida Cell's Pipeline Programs
    • GC Cell
      • Table Current Status of GC Cell's Clinical Activities
    • Genzyme Corporation
      • Epicel
    • Glycostem Therapeutics BV
      • Technology
      • oNKord
    • Hemostemix, Inc.
      • Table Hemostemix's Clinical Pipeline
    • Histogenics Corporation
    • Humacyte, Inc.
    • Immusoft Corporation
      • ISP Technology
    • Innovative Cellular Therapeutics Co., Ltd.
      • Table ICT's Pipeline Programs
    • Iovance Biotherapeutics, Inc.
      • Table Iovance's Clinical Pipeline
    • JCR Pharmaceuticals Co., Ltd.
      • TEMCELL HS Inj.
        • Table JCR's RM Products in Development
    • J-TEC
    • JW CreaGene Co., Ltd.
      • Products
    • Kadimastem Ltd.
      • AstroRx
      • Incapsulin
    • Kaneka Eurogentec S.A.
    • KBI Biopharma, Inc.
    • Kiadis Pharma N.V.
      • ATIR101
    • Kite Pharma, Inc.
      • Yescarta
        • Table Kite's CAR-T Pipeline
    • Lion TCR Pte. Ltd.
      • Table Lion TCR's Product Candidates
    • Lonza Group Ltd.
      • Custom Development and Manufacturing
    • Magenta Therapeutics, Inc.
      • Magenta's Programs
        • Table Magenta's Product Candidates
    • MaxCyte, Inc.
      • Products
    • Medigene AG
      • Table Medigene's Immunotherapy Pipeline Projects
    • MEDIPOST CO., Ltd.
      • CARTISTEM
      • PNEUMOSTEM
      • NEUROSTEM
    • Mesoblast Limited
      • Table Mesoblast's Advanced Product Candidates
    • Miromatrix Medical, Inc.
      • MIRODERM
      • MICROMESH
    • MolMed S.p.A
      • MolMed's Clinical Trial Programs
      • MolMed's GMP Solutions
        • Table MolMed's Product Candidates
    • Mustang Bio, Inc.
      • Table Mustang Bio's Product Pipeline
      • MB-101
      • MB-102
      • MB-103
      • MB-104
      • MB-105
      • MB-106
      • MB-107
    • NantKwest, Inc.
      • Table NantKwest's Clinical Trials using Cryopreserved haNK Cells
    • NexImmune, Inc.
      • Table NexImmune's Adoptive Cellular Therapy (ACT) Programs
    • Neuralstem, Inc.
      • Table Neuralstem's Cell Therapy Programs
    • Nohla Therapeutics, Inc.
      • Table Nohla's Donor Cell Therapy Programs
    • Novartis AG
      • Kymriah
    • Novasep Holding SAS
      • Biopharmaceutical Manufacturing Solutions
    • NuVasive, Inc.
      • Osteocel
      • AttraX Scaffold
    • Orgenesis, Inc.
      • MaSTHerCell
    • Orthocell Limited
    • Osiris Therapeutics, Inc.
      • Grafix
      • Grafix PL PRIME
      • Cartiform
      • BIO4
    • Orthofix Medical, Inc.
      • Trinity ELITE
      • Trinity EVOLUTION
      • VersaShield
    • Oxford BioMedica plc
      • Oxford BioMedica's Partnering Activities
        • Table Oxford BioMedica's Proprietary Product Pipeline
        • Table Oxford BioMedica's Partnered Products
        • Table Oxford BioMedica's IP Enabled and Royalty Bearing Products
    • Paragon Bioservices, Inc.
      • Services
    • Pharmicell Co., Ltd.
      • Cellgram AMI
        • Table Pharmicell's Clinical Trials for Commercialization
    • Pluristem Therapeutics, Inc.
    • Posedia Therapeutics, Inc.
      • Table Posedia's Product Pipeline
    • PROMETHERA Biosciences S.A.
      • Table PROMETHERA's Product Pipeline
    • Recipharm AB
    • Regenerative Medical System (RMS)
      • Chondron
      • Ossron
    • ReNeuron Group plc
      • Table ReNeuron's Program Pipeline
    • Richter-Helm BioLogics GmbH & Co. KG.
      • Process Development
      • Analytics
      • Production
    • RoosterBio, Inc.
      • MSCs in different Formats
      • Bioprocess Media
      • Plug & Play Systems
      • CliniControl Products
    • RoslinCT
      • Services
    • Rubius Therapeutics, Inc.
      • Table Rubius' Pipeline Programs
    • Sangamo Therapeutics, Inc.
      • Table Sangamo's Proprietary Programs
      • Table Sangamo's Proprietary Programs
    • SCM Lifesciences Co., Ltd.
      • Table SCM Lifesciences' Product Pipeline
    • Semma Therapeutics Inc.
      • SCbeta Cells
    • Sentien Biotechnologies, Inc.
      • SBI-101
        • Table Sentien's SBI-101 Clinical Programs
    • SQZ Biotechnologies
      • SQZ Platform
    • Stempeutics Research Pvt., Ltd.
      • Stempeucel
      • Stempeucare
      • Stempeutron
    • Takara Bio, Inc.
      • Services and Support
    • Terumo Corporation
      • HeartSheet
    • The Cell and Gene Therapy Catapult
      • Catapult's Industrialization Team
      • Catapult's Manufacturing Center at Stevenage
      • Catapult's Regulatory Team
    • Triumvira Immunologics USA, Inc.
      • Table Triumvira's Product Pipeline
    • TxCell S.A.
      • Technology
      • CAR-Treg Transplantation (TX200)
      • CAR-Treg Dermatology
      • CAR-Treg Multiple Sclerosis
    • Vericel Corporation
      • MACI
      • Epicel
    • ViaCyte, Inc.
      • Product Candidates
        • Table ViaCyte's Product Pipeline
    • Vibalogics GmbH
    • Voyager Therapeutics, Inc.
      • Table Voyager's Pipeline Programs
    • Waisman Biomanufacturing
      • Services and Products
    • WindMIL Therapeutics, Inc.
      • Unmodified MILs
      • MIL CARs
      • genMILs
    • Wuxi App Tec, Inc.
      • Services

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook